The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Glycemic Control and Excess Mortality in Type 1 Diabetes
Open accessAbstract
BACKGROUND: The excess risk of death from any cause and of death from cardiovascular causes is unknown among patients with type 1 diabetes and various levels of glycemic control. We conducted a registry-based observational study to determine the excess risk of death according to the level of glycemic control in a Swedish population of patients with diabetes. METHODS: We included in our study patients with type 1 diabetes registered in the Swedish National Diabetes Register after January 1, 1998. For each patient, five controls were randomly selected from the general population and matched according to age, sex, and county. Patients and controls were followed until December 31, 2011, through the Swedish Register for Cause-Specific Mortality. RESULTS: The mean age of the patients with diabetes and the controls at baseline was 35.8 and 35.7 years, respectively, and 45.1% of the participants in each group were women. The mean follow-up in the diabetes and control groups was 8.0 and 8.3 years, respectively. Overall, 2701 of 33,915 patients with diabetes (8.0%) died, as compared with 4835 of 169,249 controls (2.9%) (adjusted hazard ratio, 3.52; 95% confidence interval [CI], 3.06 to 4.04); the corresponding rates of death from cardiovascular causes were 2.7% and 0.9% (adjusted hazard ratio, 4.60; 95% CI, 3.47 to 6.10). The multivariable-adjusted hazard ratios for death from any cause according to the glycated hemoglobin level for patients with diabetes as compared with controls were 2.36 (95% CI, 1.97 to 2.83) for a glycated hemoglobin level of 6.9% or lower (≤52 mmol per mole), 2.38 (95% CI, 2.02 to 2.80) for a level of 7.0 to 7.8% (53 to 62 mmol per mole), 3.11 (95% CI, 2.66 to 3.62) for a level of 7.9 to 8.7% (63 to 72 mmol per mole), 3.65 (95% CI, 3.11 to 4.30) for a level of 8.8 to 9.6% (73 to 82 mmol per mole), and 8.51 (95% CI, 7.24 to 10.01) for a level of 9.7% or higher (≥83 mmol per mole). Corresponding hazard ratios for death from cardiovascular causes were 2.92 (95% CI, 2.07 to 4.13), 3.39 (95% CI, 2.49 to 4.61), 4.44 (95% CI, 3.32 to 5.96), 5.35 (95% CI, 3.94 to 7.26), and 10.46 (95% CI, 7.62 to 14.37). CONCLUSIONS: In our registry-based observational study, patients with type 1 diabetes and a glycated hemoglobin level of 6.9% or lower had a risk of death from any cause or from cardiovascular causes that was twice as high as the risk for matched controls. (Funded by the Swedish Society of Medicine and others.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These diseases represent the first cause of mortality even for those who achieve optimal glycemic control.140”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [140]
In the citing paper
“Improving glycaemic control is of importance due to the excess risk of mortality in those with poor glycaemic control.44”
From Acceptance and commitment therapy (ACT) for adult type 1 diabetes management: Study protocol for a randomised controlled trial (2018) · cites this paper as [44]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Wettermark, B., Hammar, N., MichaelFored, C., Leimanis, A., Otterblad Olausson, P., Bergman, U., Persson, I., Sundström, A., Westerholm, B., & Rosén, M. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1294 · Cited by 1,887
Booth, G., & Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.010 · Cited by 1,220
Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.009 · Cited by 728
Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes
Laing, S. P., Swerdlow, A. J., Slater, S. D., Burden, A. C., Morris, A., Waugh, N. R., Gatling, W., Bingley, P. J., & Patterson, C. C. (2003) · Diabetologia · doi:10.1007/s00125-003-1116-6 · Cited by 724
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes
Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., et al. (2009) · Diabetes · doi:10.2337/db08-1543 · Cited by 638
Laing, S. P., Swerdlow, A. J., Slater, S. D., Botha, J. L., Burden, A. C., Waugh, N. R., Smith, A. W. M., Hill, R. D., Bingley, P. J., Patterson, C. C., et al. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00075.x · Cited by 425
Research works printed but not linked: 1
- Parving HH, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. Brenner and Rector’s the kidney, 7th ed. Philadelphia: WB Saunders, 2004:1777-1818.
Cited by
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Registers of the Swedish total population and their use in medical research
Ludvigsson, J. F., Almqvist, C., Bonamy, A.-K. E., Ljung, R., Michaëlsson, K., Neovius, M., Stephansson, O., & Ye, W. (2016) · European Journal of Epidemiology · doi:10.1007/s10654-016-0117-y · Cited by 1,674
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Katsarou, A., Gudbjörnsdottir, S., Rawshani, A., Dabelea, D., Bonifacio, E., Anderson, B. J., Jacobsen, L. M., Schatz, D. A., & Lernmark, Å. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.16 · Cited by 1,475
Authors/Task Force Members, Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316653709 · Cited by 1,334
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
Self-citationInsel, R. A., Dunne, J. L., Atkinson, M. A., Chiang, J. L., Dabelea, D., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Krischer, J. P., Lernmark, Å., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1419 · Cited by 1,216
Excess Mortality among Persons with Type 2 Diabetes
Tancredi, M., Rosengren, A., Svensson, A.-M., Kosiborod, M., Pivodic, A., Gudbjörnsdottir, S., Wedel, H., Clements, M., Dahlqvist, S., & Lind, M. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504347 · Cited by 996
Self-citationRawshani, A., Sattar, N., Franzén, S., Rawshani, A., Hattersley, A. T., Svensson, A.-M., Eliasson, B., & Gudbjörnsdottir, S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31506-x · Cited by 802
Self-citationLind, M., Polonsky, W., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., Schwarz, E., Ólafsdóttir, A. F., Frid, A., Wedel, H., et al. (2017) · JAMA · doi:10.1001/jama.2016.19976 · Cited by 705
Self-citationThyroid dysfunction and diabetes mellitus: two closely associated disorders
Biondi, B., Kahaly, G. J., & Robertson, R. P. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00163 · Cited by 598
Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective
Zaccardi, F., Webb, D. R., Yates, T., & Davies, M. J. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2015-133281 · Cited by 561
Sattar, N., Rawshani, A., Franzén, S., Rawshani, A., Svensson, A.-M., Rosengren, A., McGuire, D. K., Eliasson, B., & Gudbjörnsdottir, S. (2019) · Circulation · doi:10.1161/circulationaha.118.037885 · Cited by 555
Self-citation2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.05.037 · Cited by 486
Survival in Children With Congenital Heart Disease: Have We Reached a Peak at 97%?
Mandalenakis, Z., Giang, K. W., Eriksson, P., Liden, H., Synnergren, M., Wåhlander, H., Fedchenko, M., Rosengren, A., & Dellborg, M. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.017704 · Cited by 430
Self-citationHuxley, R. R., Peters, S. A. E., Mishra, G. D., & Woodward, M. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70248-7 · Cited by 383
Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology
Ferrannini, E. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.011 · Cited by 340
“…in cardiovascular disease (CVD) mortality in the Western Hemisphere (Ford et al., 2007), a 2-fold gradient in CVD incidence persists between patients with type 2 (Emerging Risk Factors Collaboration et al., 2011) or type 1 diabetes (Lind et al., 2014) and the respective background populations.”
BackgroundDandona, P., Mathieu, C., Phillip, M., Hansen, L., Griffen, S. C., Tschöpe, D., Thorén, F., Xu, J., Langkilde, A. M., Proietto, J., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30308-x · Cited by 293
Rigby, M. R., Harris, K. M., Pinckney, A., DiMeglio, L. A., Rendell, M. S., Felner, E. I., Dostou, J. M., Gitelman, S. E., Griffin, K. J., Tsalikian, E., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81722 · Cited by 291
Glycemic Variability and Diabetes Complications: Does It Matter? Of Course It Does!
Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc14-2898 · Cited by 282
Adult-onset autoimmune diabetes: current knowledge and implications for management
Buzzetti, R., Zampetti, S., & Maddaloni, E. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.99 · Cited by 271
(2015) · doi:10.1136/bmj.h3234 · Cited by 258
Self-citationMathieu, C., Dandona, P., Gillard, P., Senior, P., Hasslacher, C., Araki, E., Lind, M., Bain, S. C., Jabbour, S., Arya, N., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0623 · Cited by 252
“Even when target HbA1c levels are achieved, there is still evidence for excess mortality in patients with type 1 diabetes (3).”
BackgroundSelf-citationTorkamani, A., Andersen, K. G., Steinhubl, S. R., & Topol, E. J. (2017) · Cell · doi:10.1016/j.cell.2017.08.007 · Cited by 241
Pathogenesis of Lipid Disorders in Insulin Resistance: a Brief Review
Bjornstad, P., & Eckel, R. H. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1101-6 · Cited by 243
Dandona, P., Mathieu, C., Phillip, M., Hansen, L., Tschöpe, D., Thorén, F., Xu, J., Langkilde, A. M., DEPICT-1 Investigators, Proietto, J., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1087 · Cited by 243
“Achieving and maintaining glycemic control in patients with type 1 diabetes is important, providing clear benefits in terms of preventing micro- (19) and macrovascular disease (20,21), but many patients are still failing to achieve and maintain their targets (1).”
BackgroundDiabetic Ketoacidosis at Diagnosis of Type 1 Diabetes Predicts Poor Long-term Glycemic Control
Duca, L. M., Wang, B., Rewers, M., & Rewers, A. (2017) · Diabetes Care · doi:10.2337/dc17-0558 · Cited by 236
Choudhary, P., Rickels, M. R., Senior, P. A., Vantyghem, M.-C., Maffi, P., Kay, T. W., Keymeulen, B., Inagaki, N., Saudek, F., Lehmann, R., et al. (2015) · Diabetes Care · doi:10.2337/dc15-0090 · Cited by 233
Clements, M. A., Foster, N. C., Maahs, D. M., Schatz, D. A., Olson, B. A., Tsalikian, E., Lee, J. M., Burt-Solorzano, C. M., Tamborlane, W. V., Chen, V., et al. (2016) · Pediatric Diabetes · doi:10.1111/pedi.12295 · Cited by 226
Self-citationEstimated glucose disposal rate predicts mortality in adults with type 1 diabetes
Nyström, T., Holzmann, M. J., Eliasson, B., Svensson, A., & Sartipy, U. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13110 · Cited by 213
Self-citationEstrogen: An Emerging Regulator of Insulin Action and Mitochondrial Function
Gupte, A. A., Pownall, H. J., & Hamilton, D. J. (2015) · Journal of Diabetes Research · doi:10.1155/2015/916585 · Cited by 198
Mortality in type 1 diabetes in the DCCT/EDIC versus the general population
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016) · Diabetes Care · doi:10.2337/dc15-2399 · Cited by 194
Rawshani, A., Rawshani, A., Sattar, N., Franzén, S., McGuire, D. K., Eliasson, B., Svensson, A.-M., Zethelius, B., Miftaraj, M., Rosengren, A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037454 · Cited by 177
“Proportion of overall chi square Lipid medication (2) Immigrant (1) Body mass index (3) Systolic blood pressure (3) Smoking (1) Education (2) Blood pressure mediation (2) Duration of diabetes (3) Income (4) Physical inactivity (4) Albuminuria (2) eGFR (3) LDL-cholesterol (3) Glycated hemoglobin (3)”
BackgroundInfluentialSelf-citationLind, M., Pivodic, A., Svensson, A.-M., Ólafsdóttir, A. F., Wedel, H., & Ludvigsson, J. (2019) · BMJ · doi:10.1136/bmj.l4894 · Cited by 175
Self-citationRawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · Circulation · doi:10.1161/circulationaha.116.025961 · Cited by 167
Self-citationF. Piepoli, M. (2017) · International Journal of Behavioral Medicine · doi:10.1007/s12529-016-9583-6 · Cited by 162
Pugliese, G., Penno, G., Natali, A., Barutta, F., Di Paolo, S., Reboldi, G., Gesualdo, L., & De Nicola, L. (2019) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.07.017 · Cited by 156
Ólafsdóttir, A. F., Attvall, S., Sandgren, U., Dahlqvist, S., Pivodic, A., Skrtic, S., Theodorsson, E., & Lind, M. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0392 · Cited by 173
Self-citationType 1 diabetes mellitus: much progress, many opportunities
Powers, A. C. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142242 · Cited by 192
Cardiovascular outcomes in type 1 and type 2 diabetes
Rosengren, A., & Dikaiou, P. (2023) · Diabetologia · doi:10.1007/s00125-022-05857-5 · Cited by 177
Self-citationCardiovascular Risk in Type 1 Diabetes Mellitus
Schofield, J. D., Ho, J. H., & Soran, H. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0612-8 · Cited by 177
Lee, Y.-B., Han, K., Kim, B., Lee, S.-E., Jun, J. E., Ahn, J., Kim, G., Jin, S.-M., & Kim, J. H. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0953-7 · Cited by 131
Glycaemic management in diabetes: old and new approaches
Ceriello, A., Prattichizzo, F., Phillip, M., Hirsch, I. B., Mathieu, C., & Battelino, T. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00245-x · Cited by 165
Diabetes and ageing‐induced vascular inflammation
Assar, M. E., Angulo, J., & Rodríguez‐Mañas, L. (2015) · The Journal of Physiology · doi:10.1113/jp270841 · Cited by 150
“Diabetes represents an important risk factor for CVD (Sarwar et al. 2010; Lind et al. 2014; Peters et al. 2014).”
BackgroundMarfella, R., Scisciola, L., D’Onofrio, N., Maiello, C., Trotta, M. C., Sardu, C., Panarese, I., Ferraraccio, F., Capuano, A., Barbieri, M., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106448 · Cited by 139
Ischemic Stroke in Children and Young Adults With Congenital Heart Disease
Mandalenakis, Z., Rosengren, A., Lappas, G., Eriksson, P., Hansson, P., & Dellborg, M. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.003071 · Cited by 137
Self-citationHuo, L., Harding, J. L., Peeters, A., Shaw, J. E., & Magliano, D. J. (2016) · Diabetologia · doi:10.1007/s00125-015-3857-4 · Cited by 154
“chronic complications are key contributors to reduced life expectancy for type 1 diabetic patients [2, 6].”
BackgroundXue, C., Chen, K., Gao, Z., Bao, T., Dong, L., Zhao, L., Tong, X., & Li, X. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-022-01016-w · Cited by 161
The Burden of Diabetes: Emerging Data
Maffi, P., & Secchi, A. (2017) · Developments in ophthalmology · doi:10.1159/000459641 · Cited by 152
Miller, R. G., Mahajan, H., Costacou, T., Sekikawa, A. M., Anderson, S., & Orchard, T. J. (2016) · Diabetes Care · doi:10.2337/dc16-1162 · Cited by 128
the Italian Diabetes Society and the Italian Society of Nephrology, Pugliese, G., Penno, G., Natali, A., Barutta, F., Paolo, S. D., Reboldi, G., Gesualdo, L., & Nicola, L. D. (2019) · Journal of Nephrology · doi:10.1007/s40620-019-00650-x · Cited by 153
Cytochrome P450-derived eicosanoids and heart function
Jamieson, K. L., Endo, T. H., Darwesh, A. M., Samokhvalov, V., & Seubert, J. M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.05.005 · Cited by 128
Sousa, G. R., Pober, D., Galderisi, A., Lv, H., Yu, L., Pereira, A. C., Doria, A., Kosiborod, M., & Lipes, M. A. (2019) · Circulation · doi:10.1161/circulationaha.118.036068 · Cited by 117
“0% group; (3) the number of cardiac AAbs produced; and (4) the antigenic specificities of the AAbs.”
Self-citationWang, M.-Y., Yan, H., Shi, Z., Evans, M. R., Yu, X., Lee, Y., Chen, S., Williams, A., Philippe, J., Roth, M. G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424934112 · Cited by 112
Vergès, B. L. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.09.001 · Cited by 126
Disordered haematopoiesis and athero-thrombosis
Murphy, A. J., & Tall, A. R. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv718 · Cited by 116
Adherence of self-monitoring of blood glucose in persons with type 1 diabetes in Sweden
Moström, P., Ahlén, E., Imberg, H., Hansson, P. O., & Lind, M. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000342 · Cited by 129
Self-citationBjörnsdóttir, H. H., Rawshani, A., Rawshani, A., Franzén, S., Svensson, A., Sattar, N. A., & Guðbjörnsdóttir, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-73668-y · Cited by 113
Self-citationDiabetes Prevalence in Sweden at Present and Projections for Year 2050
Andersson, T., Ahlbom, A., & Carlsson, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143084 · Cited by 117
Recent trends in life expectancy for people with type 1 diabetes in Sweden
Petrie, D., Lung, T. W.-C., Rawshani, A., Palmer, A. J., Svensson, A., Eliasson, B., & Clarke, P. (2016) · Diabetologia · doi:10.1007/s00125-016-3914-7 · Cited by 107
Self-citationKuhadiya, N. D., Dhindsa, S., Ghanim, H., Mehta, A., Makdissi, A., Batra, M., Sandhu, S., Hejna, J., Green, K., Bellini, N., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1136 · Cited by 101
Care of diabetes in children and adolescents: controversies, changes, and consensus
Cameron, F. J., & Wherrett, D. K. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60971-0 · Cited by 99
BMI, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes: Findings Against an Obesity Paradox
Edqvist, J., Rawshani, A., Adiels, M., Bjorck, L. M., Lind, M., Svensson, A., Gudbjörnsdottir, S., Sattar, N. A., & Rosengren, A. (2019) · Diabetes Care · doi:10.2337/dc18-1446 · Cited by 116
Self-citationBreton, M. D., Patek, S. D., Lv, D., Schertz, E. M., Robic, J., Pinnata, J., Kollar, L. L., Barnett, C. L., WAKEMAN, C. A., Oliveri, M. C., et al. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0079 · Cited by 103
Colom, C., Rull, A., Sánchez‐Quesada, J. L., & Pérez, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081798 · Cited by 117
Islet Encapsulation: Physiological Possibilities and Limitations
Korsgren, O. (2017) · Diabetes · doi:10.2337/db17-0065 · Cited by 100
Musso, G., Gambino, R., Cassader, M., & Paschetta, E. (2019) · BMJ · doi:10.1136/bmj.l1328 · Cited by 102
van Raalte, D. H., Bjornstad, P., Persson, F., Powell, D. R., Castro, R. D. C., Wang, P. S., Liu, M., Heerspink, H. J. L., & Cherney, D. Z. I. (2019) · Diabetes Care · doi:10.2337/dc19-0937 · Cited by 99
Wherrett, D. K., Chiang, J. L., Delamater, A. M., DiMeglio, L. A., Gitelman, S. E., Gottlieb, P. A., Herold, K. C., Lovell, D. J., Orchard, T. J., Ryan, C. M., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1429 · Cited by 105
Bjornstad, P., Donaghue, K. C., & Maahs, D. M. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30035-4 · Cited by 107
“Furthermore, optimal glycemic control (HbA1c <7%) may not sufficiently abolish CVD risk in T1D (2, 20) (Supplemental Table 1).”
BackgroundKristófi, R., Bodegård, J., Norhammar, A., Thuresson, M., Nathanson, D., Nyström, T., Birkeland, K. I., & Eriksson, J. W. (2021) · Diabetes Care · doi:10.2337/dc20-2839 · Cited by 98
Avdic, T., Franzén, S., Zarrouk, M., Acosta, S., Nilsson, P. M., Gottsäter, A., Svensson, A., Guðbjörnsdóttir, S., & Eliasson, B. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007618 · Cited by 100
Self-citationDiagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T., Karges, B., Kordonouri, O., et al. (2016) · Diabetologie und Stoffwechsel · doi:10.1055/s-0042-111213 · Cited by 91
Rosengren, A., Vestberg, D., Svensson, A., Kosiborod, M., Clements, M. A., Rawshani, A., Pivodic, A., Guðbjörnsdóttir, S., & Lind, M. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00292-2 · Cited by 91
Self-citationCauses of death in childhood‐onset Type 1 diabetes: long‐term follow‐up
Gagnum, V., Stene, L. C., Jenssen, T. G., Berteussen, L. M., Sandvik, L., Joner, G., Njølstad, P. R., & Skrivarhaug, T. (2017) · Diabetic Medicine · doi:10.1111/dme.13114 · Cited by 87
Engström, M. S., Leksell, J. K., Johansson, U., & Guðbjörnsdóttir, S. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010249 · Cited by 106
The Gut-Kidney Axis: Putative Interconnections Between Gastrointestinal and Renal Disorders
Lehto, M. J., & Groop, P. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00553 · Cited by 89
“Both are chronic diseases that are associated with increased risk of cardiovascular disease and premature mortality (33, 34).”
BackgroundHanssen, N. M. J., Scheijen, J. L. J. M., Jorsal, A., Parving, H., Tarnow, L., Rossing, P. R., Stehouwer, C. D. A., & Schalkwijk, C. G. (2017) · Diabetes · doi:10.2337/db16-1578 · Cited by 89
Ludvigsson, J. F., Neovius, M., Söderling, J. K., Guðbjörnsdóttir, S., Svensson, A., Franzén, S., Stephansson, O., & Pasternak, B. (2018) · BMJ · doi:10.1136/bmj.k2638 · Cited by 89
Self-citationA Longitudinal Examination of Hope and Optimism and Their Role in Type 1 Diabetes in Youths
Allen, J. V., Steele, R. G., Nelson, M. B., Peugh, J., Egan, A. M., Clements, M. A., & Patton, S. R. (2015) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsv113 · Cited by 86
Self-citationGarofolo, M., Gualdani, E., GIANNARELLI, R., Aragona, M., Campi, F., Lucchesi, D., Daniele, G., Miccoli, R., Francesconi, P., Prato, S. D., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0961-7 · Cited by 86
Evolution of Diabetes Technology
Dovč, K., & Battelino, T. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.009 · Cited by 132
Prandi, F. R., Evangelista, I., Sergi, D., Palazzuoli, A., & Romeo, F. (2022) · Heart Failure Reviews · doi:10.1007/s10741-021-10200-y · Cited by 91
Lv, Y.-Q., Yuan, L., Sun, Y., Dou, H.-W., Su, J.-H., Hou, Z.-P., Li, J.-Y., & Li, W. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00288-z · Cited by 82
Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance
Apostolopoulou, M., Lambadiari, V., Roden, M., & Dimitriadis, G. D. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnae032 · Cited by 90
Ohlsson, C., Bygdell, M., Sondén, A., Rosengren, A., & Kindblom, J. M. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30273-x · Cited by 83
Self-citationThe state of the art of islet transplantation and cell therapy in type 1 diabetes
Pellegrini, S., Cantarelli, E., Sordi, V., Nano, R., & Piemonti, L. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0847-z · Cited by 82
“Although lifesaving, insulin therapy does not restore the physiological regulation of blood glucose [1] and is not able to prevent either the dangerous states of hypoglycemia or long-term complications [2] and the life expectancy of these patients is still shorter compared to that of the general population [3].”
BackgroundHero, C., Rawshani, A., Svensson, A.-M., Franzén, S., Eliasson, B., Eeg-Olofsson, K., & Gudbjörnsdottir, S. (2016) · Diabetes Care · doi:10.2337/dc15-2450 · Cited by 78
Self-citationCarlsen, S., Skrivarhaug, T., Thue, G., Cooper, J. G., Gøransson, L. G., Løvaas, K. F., & Sandberg, S. (2016) · Pediatric Diabetes · doi:10.1111/pedi.12372 · Cited by 81
The Peripheral Peril: Injected Insulin Induces Insulin Insensitivity in Type 1 Diabetes
Gregory, J. M., Cherrington, A. D., & Moore, D. J. (2020) · Diabetes · doi:10.2337/dbi19-0026 · Cited by 76
Holzmann, M. J., Rathsman, B., Eliasson, B., Kuhl, J., Svensson, A., Nyström, T., & Sartipy, U. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.052 · Cited by 76
Self-citationDenimal, D. (2023) · Antioxidants · doi:10.3390/antiox13010057 · Cited by 93
Ahmed, F. W., Rider, R., Glanville, M., Narayanan, K., Razvi, S., & Weaver, J. U. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0413-6 · Cited by 74
ISPAD Clinical Practice Consensus Guidelines 2022: Managing diabetes in preschoolers
Sundberg, F., de Beaufort, C. E., Krogvold, L., Patton, S. R., Piloya, T., Smart, C. E., Name, M. A. V., Weissberg-Benchell, J. A., da Silva, J. S. P., & DiMeglio, L. A. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13427 · Cited by 97
Rickels, M. R. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14214 · Cited by 71
“2) and makeup just under 10% of the population with T1D.35 Moreover, over half of all episodes of severe hypoglycemia are experienced by ∼5% of individuals with T1D.34 Clinically, individuals with T1D who experience mild hypoglycemia most often are more likely to remain asymptomatic and also have a significantly incre…”
BackgroundInfluentialBMI increase through puberty and adolescence is associated with risk of adult stroke
Ohlsson, C., Bygdell, M., Sondén, A., Jern, C., Rosengren, A., & Kindblom, J. M. (2017) · Neurology · doi:10.1212/wnl.0000000000004158 · Cited by 80
Self-citationDahlqvist, S., Rosengren, A., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Kosiborod, M., Svensson, A.-M., & Lind, M. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30262-0 · Cited by 70
Self-citationClausen, T. D., Bergholt, T., Bouaziz, O., Arpi, M., Eriksson, F., Rasmussen, S. C., Keiding, N., & Løkkegaard, E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161654 · Cited by 72
Overweight and obesity in type 1 diabetes equal those of the general population
Fellinger, P., Fuchs, D., Wolf, P., Heinze, G., Luger, A., Krebs, M., & Winhofer, Y. (2019) · Wiener Klinische Wochenschrift · doi:10.1007/s00508-018-1434-9 · Cited by 70
Luo, W., Lin, K., Hua, J., Han, J., Zhang, Q., Chen, L., Khan, Z. A., Wu, G., Wang, Y., & Liang, G. (2022) · Advanced Science · doi:10.1002/advs.202202590 · Cited by 83
Metadata
- Authors
- Lind, M., Svensson, A.-M., Kosiborod, M., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Dahlqvist, S., Clements, M., & Rosengren, A.
- Affiliations
- Children's Mercy Hospital (US)
- Region Västra Götaland (SE)
- Saint Luke's Hospital (US)
- Nordic School of Public Health (SE)
- Sahlgrenska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-11-20
- Volume
- 371
- Issue
- 21
- Pages
- 1972-1982
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2079297835
- Cited by
- 964
- References
- 31
- Citations by year
- 2026: 50 · 2025: 72 · 2024: 63 · 2023: 92 · 2022: 87 · 2021: 81 · 2020: 94 · 2019: 82 · 2018: 83 · 2017: 70 · 2016: 102 · 2015: 82 · 2014: 2
- FWCI
- 68.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Edwards Lifesciences
- Västra Götalandsregionen
- Regeneron Pharmaceuticals
- Dexcom
- Novo Nordisk
- Vetenskapsrådet ([2013-5187, 2013-4236])
- Svenska Läkaresällskapet
- Genentech
- Health and Medical Care Committee of the Regional Executive Board, Region Västra Götaland
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 1 diabetes, glycemic control, HbA1c, excess mortality, cardiovascular mortality, all-cause mortality, HbA1c thresholds, mortality risk, diabetes registry, Swedish National Diabetes Register, diabetes management guidelines, diabetes self-management education
- MeSH terms
- Adult, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Male, Middle Aged, Registries, Risk, Sweden, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.